Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FMmeds vs NowPatient

FMmeds
Graded #257

Lower grade

vs+2.299999999999997
NowPatient
Graded #217

Higher grade

The verdict

NowPatient takes it — 65.5/100 to 63.2/100.

NowPatient grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFMmeds +11
46
35
Dose & formulationNowPatient +21
72
93
Clinical oversightNowPatient +16
70
86
Labs & monitoringNowPatient +1
53
54
FulfillmentFMmeds +27
97
70
Contract termsNowPatient +8
47
55
FMmeds · left barNowPatient · right bar

The numbers

MetricFMmedsNowPatient
WeighScore63.2/10065.5/100
GradeCC
Scorecard rank#257#217
Semaglutide$225/mo (all doses, compounded)$1,349/mo (brand Wegovy)
Tirzepatide$265/mo (all doses, compounded)$1,069/mo (brand Mounjaro, promotional rate)
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
FMmeds

Graded #257 · C

Strengths

  • All 50 states plus DC covered, stated in the Terms
  • Operating LLC and full Manhattan Beach, CA address disclosed
  • Named 503A pharmacy partner (Manifest Pharmacy, Greer SC)
  • Aggressive 12-month pricing — semaglutide $95/mo and tirzepatide $145/mo, at the low end of the market
  • Flat pricing across all dose strengths — no dose-escalation surcharge

Where it loses points

  • Compounded only — no FDA-approved Wegovy, Ozempic, Mounjaro, or Zepbound
  • Publishes the FDA compounded-medication disclaimer (medication is not FDA-approved)
  • Clinical network not separately named
  • LegitScript Certified, but the specific ID isn't shown
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
NowPatient

Graded #217 · C

Strengths

  • Free telehealth consultation — you only pay for the medication
  • Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
  • One of the few platforms offering Wegovy in both injection and oral pill form
  • No compounded options — every drug is FDA-approved brand-name

Where it loses points

  • Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
  • No compounded semaglutide or tirzepatide (usually the cheaper route)
  • State availability determined during intake, not shown upfront
  • Does not offer Foundayo (orforglipron)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard